[Translation] A multicenter, randomized, parallel, open trial comparing the efficacy and safety of this product (Puxiulin 30R) and Novolin 30R in the treatment of type 2 diabetes

比较精蛋白重组人胰岛素注射液（预混30R）（普秀霖30R）与诺和灵30R治疗糖尿病的有效性和安全性。

[Translation]

To compare the efficacy and safety of protamine recombinant human insulin injection (premixed 30R) (Puxiulin 30R) and Novolin 30R in the treatment of diabetes.

Start Date-

Sponsor / Collaborator-

CTR20131068 / Active, not recruitingPhase 3

多中心、随机平行、开放试验比较本品（普秀霖30R）与诺和灵30R治疗2型糖尿病的有效性和安全性

[Translation] A multicenter, randomized, parallel, open trial comparing the efficacy and safety of this product (Puxiulin 30R) and Novolin 30R in the treatment of type 2 diabetes

比较精蛋白重组人胰岛素注射液（预混30R）（普秀霖30R）与诺和灵30R治疗糖尿病的有效性和安全性。

[Translation]

To compare the efficacy and safety of protamine recombinant human insulin injection (premixed 30R) (Puxiulin 30R) and Novolin 30R in the treatment of diabetes.

Start Date-

Sponsor / Collaborator-

CTR20131064 / Active, not recruitingPhase 3

多中心、随机平行、开放试验比较本品（普秀霖30R）与诺和灵30R治疗2型糖尿病的有效性和安全性

[Translation] A multicenter, randomized, parallel, open trial comparing the efficacy and safety of this product (Puxiulin 30R) and Novolin 30R in the treatment of type 2 diabetes

比较精蛋白重组人胰岛素注射液（预混30R）（普秀霖30R）与诺和灵30R治疗糖尿病的有效性和安全性。

[Translation]

To compare the efficacy and safety of protamine recombinant human insulin injection (premixed 30R) (Puxiulin 30R) and Novolin 30R in the treatment of diabetes.

Start Date-

Sponsor / Collaborator-

100 Clinical Results associated with Mixed Protamine Human Insulin Injection (30R)

100 Translational Medicine associated with Mixed Protamine Human Insulin Injection (30R)

100 Patents (Medical) associated with Mixed Protamine Human Insulin Injection (30R)

100 Deals associated with Mixed Protamine Human Insulin Injection (30R)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	CN	Gan & Lee Pharmaceuticals Co., Ltd.	19 May 2021
Diabetes Mellitus, Type 2	CN	Gan & Lee Pharmaceuticals Co., Ltd.	19 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	CN	-	31 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis